Germany's Bayer to buy US gene therapy specialist AskBio
|
October 27, 2020 12:03 AM
BERLIN (AP) — German health care company Bayer said Monday it is buying Asklepios BioPharmaceutical, a U.S.-based firm specializing in gene therapy, in a deal worth up to $4 billion.
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
